Literature DB >> 32226459

Specific elimination of coxsackievirus B3 infected cells with a protein engineered toxin-antitoxin system.

Jung-Ho Park1, Jin-Ho Park2, Wonho Choi1, Byung-Kwan Lim2.   

Abstract

BACKGROUNDS: Coxsackievirus B3 (CVB3) is a member of the family Picornaviridae, and along with polio-viruses, belongs to the Enterovirus genus. The CVB3 genome is composed single-stranded RNA encoding polyproteins, which are cleaved to individual functional proteins by 2A and 3C proteases proteins which have been targeted for drug development. Here, we showed that protease activity required to activate a toxic protein may be used to prevent viral infection.
METHODS: We modified the MazE-MazF antitoxin-toxin system of Escherichia coli to fuse a C-terminal fragment of MazE to the N-terminal end of toxin MazF with a linker having a specific protease cleavage site for CVB3. This fusion protein formed a stable dimer and was capable of inactivating the mRNA interferase activity of MazF which cleaves the ACA sequence in mRNA substrates.
RESULTS: The incubation of 2A proteases with the fusion proteins induced cleavage between the MazE and MazF fragments from the fusion proteins; the subsequent release of MazF significantly inhibited virus replication. Additionally, we note that, CVB3 infected HeLa cells quickly died through a MazF toxin mediated effect before virus protein expression.
CONCLUSION: These findings suggest that the MazEF fusion protein has a strong potential to be developed as an anti-virus therapy following CVB3 infection. © The Korean Society of Toxicogenomics and Toxicoproteomics and Springer Nature B.V. 2019.

Entities:  

Keywords:  Antitoxin; Cardiotropic; Coxsackievirus; MazEF; Polyprotein; Proteases

Year:  2019        PMID: 32226459      PMCID: PMC7097453          DOI: 10.1007/s13273-019-0046-4

Source DB:  PubMed          Journal:  Mol Cell Toxicol        ISSN: 1738-642X            Impact factor:   1.080


  21 in total

Review 1.  The immune system in viral myocarditis: maintaining the balance.

Authors:  K U Knowlton; C Badorff
Journal:  Circ Res       Date:  1999-09-17       Impact factor: 17.367

2.  Crystal structure of the MazE/MazF complex: molecular bases of antidote-toxin recognition.

Authors:  Katsuhiko Kamada; Fumio Hanaoka; Stephen K Burley
Journal:  Mol Cell       Date:  2003-04       Impact factor: 17.970

3.  Intramolecular regulation of the sequence-specific mRNA interferase activity of MazF fused to a MazE fragment with a linker cleavable by specific proteases.

Authors:  Jung-Ho Park; Yoshihiro Yamaguchi; Masayori Inouye
Journal:  Appl Environ Microbiol       Date:  2012-03-23       Impact factor: 4.792

4.  Translation-dependent mRNA cleavage by YhaV in Escherichia coli.

Authors:  Wonho Choi; Yoshihiro Yamaguchi; Jae-Woo Lee; Kyung-Min Jang; Masayori Inouye; Sung-Gun Kim; Min-Ho Yoon; Jung-Ho Park
Journal:  FEBS Lett       Date:  2017-06-26       Impact factor: 4.124

5.  Coxsackievirus B3 murine myocarditis: wide pathologic spectrum in genetically defined inbred strains.

Authors:  A Herskowitz; K W Beisel; L J Wolfgram; N R Rose
Journal:  Hum Pathol       Date:  1985-07       Impact factor: 3.466

6.  Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy.

Authors:  Dingding Xiong; Toshitaka Yajima; Byung-Kwan Lim; Antine Stenbit; Andrew Dublin; Nancy D Dalton; Daphne Summers-Torres; Jeffery D Molkentin; Herve Duplain; Rainer Wessely; Ju Chen; Kirk U Knowlton
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

7.  Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis.

Authors:  Soo-Hyeon Yun; Won Gil Lee; Yong-Chul Kim; Eun-Seon Ju; Byung-Kwan Lim; Jin-Oh Choi; Duk-Kyung Kim; Eun-Seok Jeon
Journal:  J Infect Dis       Date:  2011-12-29       Impact factor: 5.226

8.  Functional Characterization of the C-Terminus of YhaV in the Escherichia coli PrlF-YhaV Toxin-Antitoxin System.

Authors:  Wonho Choi; Min-Ho Yoon; Jung-Ho Park
Journal:  J Microbiol Biotechnol       Date:  2018-06-28       Impact factor: 2.351

9.  Soluble coxsackievirus B3 3C protease inhibitor prevents cardiomyopathy in an experimental chronic myocarditis murine model.

Authors:  Byung-Kwan Lim; Soo-Hyeon Yun; Eun-Seon Ju; Bo-Kyoung Kim; You-Jung Lee; Dong-Kyeom Yoo; Young-Chul Kim; Eun-Seok Jeon
Journal:  Virus Res       Date:  2014-12-05       Impact factor: 3.303

10.  Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart.

Authors:  Byung-Kwan Lim; Dingding Xiong; Andrea Dorner; Tae-Jin Youn; Aaron Yung; Taylor I Liu; Yusu Gu; Nancy D Dalton; Adam T Wright; Sylvia M Evans; Ju Chen; Kirk L Peterson; Andrew D McCulloch; Toshitaka Yajima; Kirk U Knowlton
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.